Lake Street analyst Frank Takkinen lowered the firm’s price target on Inotiv (NOTV) to $5 from $6 and keeps a Buy rating on the shares. Inotiv’s recovery “continues to trend favorably,” but the firm is taking a more conservative stance with its revenue and EBITDA estimates as it now believes its prior view of the recovery ramp was “too steep,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOTV:
- Inotiv, Inc. Reports Improved Q2 Fiscal 2025 Results
- Inotiv, Inc. (NOTV) Q2 Earnings Cheat Sheet
- Lake Street doesn’t expect Inotiv financial impact from FDA ‘headline noise’
- Inotiv drops after FDA says phasing out animal testing of monoclonal antibodies
- Sea Pharmaceuticals announces strategic relationship with Inotiv